Breaking News, Financial News

AstraZeneca 4Q Results

Revenues up 18% in the quarter driven by oncology and respiratory sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: AstraZeneca

AstraZeneca4Q Revenues: $14.9 billion (+24%)4Q Earnings: $1.5 billion (+56%)FY Revenues: $54.1 billion (+18%)FY Earnings: $7.0 billion (+18%)Comments: Oncology sales were $22.4 billion, up 21%. Tagrisso sales were $1.7 billion in the quarter, up 20%. Imfinzi sales were $1.3 billion, up 16%. Lynparza sales were up 46% to $1.4 billion. Cardiovascular, Renal and Metabolism (CVRM) sales were up 16% in the quarter. Farxiga sales were up 21% to $1.9 billion. Brilinta sales were $341 million, up 4%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters